Sit Investment Associates Inc. Makes New Investment in Boston Scientific Corporation $BSX

Sit Investment Associates Inc. acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 27,240 shares of the medical equipment provider’s stock, valued at approximately $2,597,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. MidFirst Bank bought a new position in Boston Scientific in the fourth quarter worth approximately $190,000. Sonoma Allocations LLC boosted its stake in Boston Scientific by 22.9% in the fourth quarter. Sonoma Allocations LLC now owns 3,883 shares of the medical equipment provider’s stock valued at $361,000 after acquiring an additional 724 shares during the last quarter. Kera Capital Partners Inc. grew its stake in shares of Boston Scientific by 47.5% during the 4th quarter. Kera Capital Partners Inc. now owns 5,025 shares of the medical equipment provider’s stock worth $470,000 after acquiring an additional 1,618 shares during the period. Virtu Financial LLC boosted its position in Boston Scientific by 13.4% during the fourth quarter. Virtu Financial LLC now owns 12,871 shares of the medical equipment provider’s stock worth $1,227,000 after purchasing an additional 1,519 shares during the period. Finally, MV Capital Management Inc. purchased a new position in Boston Scientific in the 4th quarter valued at approximately $80,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Edward J. Ludwig acquired 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 9,800 shares of company stock worth $554,012 in the last three months. Insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $45.30 on Friday. Boston Scientific Corporation has a fifty-two week low of $44.44 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The company has a market capitalization of $67.33 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 0.87 and a beta of 0.56. The company has a 50 day simple moving average of $54.71 and a two-hundred day simple moving average of $73.03.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts expect that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of research firms have weighed in on BSX. Canaccord Genuity Group decreased their price target on Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. Stifel Nicolaus set a $75.00 price target on Boston Scientific in a research note on Wednesday, May 27th. Piper Sandler reaffirmed an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research note on Friday, June 12th. Mizuho reduced their price target on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Finally, Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.08.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.